Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified.Refs:[6][7][4][8][9][10][11][3][12]
The sizeable number of serotonergic drugs for treating migraines all incorporate the indole nucleus found in serotonin itself. It is thus of interest that a compound based on abenzopyran manifests much the same activity.
^abRamadan NM (2001). "Acute treatments: some blind alleys".Curr Med Res Opin. 17 Suppl 1: s71–80.doi:10.1185/0300799039117001.PMID12463283.[...] Finally, alniditan has a long plasma half-life (8–13 h).
^ab"Alniditan".AdisInsight. 8 July 1997. Retrieved28 July 2025.
^abcdefRubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJ, Zanelli E, Meeus L, Danser AH, Gralinski MR, Senese PB, Johnson KW, Kovalchin J, Villalón CM, MaassenVanDenBrink A (December 2019)."Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan".British Journal of Pharmacology.176 (24):4681–4695.doi:10.1111/bph.14832.PMC6965684.PMID31418454.TABLE 1 Summary of pIC50 (negative logarithm of the molar concentration of these compounds at which 50% of the radioligand is displaced) and pKi (negative logarithm of the molar concentration of the Ki ) values of individual antimigraine drugs at 5‐HT receptors [...] TABLE 2 Summary of pEC50 values of cAMP (5‐HT1A/B/E/F and 5‐HT7), GTPγS (5‐HT1A/B/D/E/F), and IP (5‐HT2) assays of individual antimigraine drugs at 5‐HT receptors [...]
^abcdeLeysen JE, Gommeren W, Heylen L, Luyten WH, Van de Weyer I, Vanhoenacker P, Haegeman G, Schotte A, Van Gompel P, Wouters R, Lesage AS (December 1996). "Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan".Mol Pharmacol.50 (6):1567–1580.doi:10.1016/S0026-895X(25)09616-6.PMID8967979.
^Ramadan NM, Skljarevski V, Phebus LA, Johnson KW (October 2003). "5-HT1F receptor agonists in acute migraine treatment: a hypothesis".Cephalalgia.23 (8):776–785.doi:10.1046/j.1468-2982.2003.00525.x.PMID14510923.
^abPerez, M.; Halazy, S.; Pauwels, P.J.; Colpaert, F.C.; John, G.W. (1999)."F-11356".Drugs of the Future.24 (6): 0605.doi:10.1358/dof.1999.024.06.537284. Retrieved23 June 2025.
^Van Lommen G, De Bruyn M, Schroven M, Verschueren W, Janssens W, Verrelst J, Leysen J (1995). "The discovery of a series of new non-indole 5HT1D agonists".Bioorganic & Medicinal Chemistry Letters.5 (22):2649–2654.doi:10.1016/0960-894X(95)00473-7.
